ポスターダウンロード_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

ゲノム編集

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

資料ダウンロード

ポスターダウンロード

ニュース & PR

世界に通用する跳躍

ニュースリリース

キャンペーン一覧

ウェビナー

発表論文一覧

資料ダウンロード

ポスターダウンロード

製品資料ダウンロード

PEGS-EU 2022:1C3—A Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy

PEGS-EU 2022:A Novel TCR-mimic Fully Human Antibodies Discovery Platform

World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors

ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors

AACR 2025: BCG033: a first-in-class PTK7×TROP2 bispecific ADC demonstrating potent and broad efficacy in various preclinical models

AACR 2025: BCG014: A CDH3-targeting ADC with a novel TOP1 inhibitor demonstrates robust anti-tumor efficacy in PDX models

AACR 2025: YH006: a next-generation CTLA-4×OX40 Treg antagonist, demonstrates superior tumor-infiltrating Treg-depletion efficacy and favorable manufacturability

AACR 2022: Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

1 … 9 10 11 12 13 14